Eurofins Scientific SE Stock London S.E.
Stocks
0MV5
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.70 EUR | +1.46% |
|
+3.14% | +11.89% |
| 07-23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
| Market Cap | 12.1B 13.97B 11.28B 10.37B 19.58B 1,328B 19.8B 133B 52.01B 664B 52.46B 51.3B 2,201B | P/E 2026 * |
23.2x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 15.45B 17.83B 14.4B 13.24B 25B 1,696B 25.28B 169B 66.4B 848B 66.98B 65.5B 2,810B | EV / Sales 2026 * |
2.03x | EV / Sales 2027 * | 1.89x |
| Free-Float |
60.39% | Yield 2026 * |
1.16% | Yield 2027 * | 1.32% |
Last Transcript: Eurofins Scientific SE
| 1 day | +1.46% | ||
| 1 week | +3.14% | ||
| Current month | +1.45% | ||
| 1 month | +0.86% | ||
| 3 months | +19.35% | ||
| 6 months | +2.27% | ||
| Current year | +11.89% |
| 1 week | 67.5 |  | 69.8 |
| 1 month | 64.8 | | 71.28 |
| Current year | 56.86 | | 74.28 |
| 1 year | 56.24 | | 74.28 |
| 3 years | 39.6 | | 74.28 |
| 5 years | 39.6 | | 127.54 |
| 10 years | 30.14 | | 127.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | +3.14% | - | - | 13.76B | |
| +0.90% | -2.33% | +0.68% | +13.87% | 48B | |
| +1.98% | +9.05% | +413.94% | +532.17% | 41.13B | |
| +3.44% | -4.65% | +28.34% | +8.81% | 37.56B | |
| +1.40% | +0.10% | +6.61% | +61.93% | 35.91B | |
| +2.42% | +5.72% | +12.38% | +44.79% | 29.86B | |
| -0.16% | -3.11% | - | - | 16.12B | |
| +2.20% | +0.48% | +34.71% | +127.15% | 16.05B | |
| +4.25% | -8.23% | -1.49% | -35.46% | 12.1B | |
| +11.36% | +11.04% | +55.66% | +26.01% | 11.28B | |
| Average | +2.92% | +0.30% | +68.85% | +97.41% | 27.56B | |
| Weighted average by Cap. | +2.33% | +0.41% | +85.80% | +122.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.59B 8.77B 7.08B 6.51B 12.29B 833B 12.42B 83.16B 32.64B 417B 32.92B 32.2B 1,381B | 8.01B 9.25B 7.47B 6.87B 12.97B 880B 13.11B 87.78B 34.45B 440B 34.75B 33.98B 1,458B |
| Net income | 532M 615M 496M 456M 861M 58.43B 871M 5.83B 2.29B 29.24B 2.31B 2.26B 96.83B | 661M 763M 616M 567M 1.07B 72.57B 1.08B 7.24B 2.84B 36.31B 2.87B 2.8B 120B |
| Net Debt | 3.35B 3.87B 3.12B 2.87B 5.42B 368B 5.48B 36.68B 14.4B 184B 14.52B 14.2B 609B | 3.01B 3.48B 2.81B 2.58B 4.88B 331B 4.93B 33B 12.95B 165B 13.06B 12.78B 548B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-05 | €69.29 | +1.03% | 5,688 |
| 26-08-04 | €68.58 | +1.60% | 169,479 |
| 26-08-03 | €67.50 | -1.75% | 41,051 |
| 26-07-31 | €68.70 | +0.21% | 12,930 |
| 26-07-30 | €68.56 | +1.45% | 26,162 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
- 0MV5 Stock
Select your edition
All financial news and data tailored to specific country editions
